导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.74% | 2213/4773 |
| 近一周 | -3.26% | 4666/5465 |
| 近一月 | -0.43% | 822/5421 |
| 近一季 | 0.74% | 847/5231 |
| 近半年 | -5.66% | 3067/4920 |
| 近一年 | -1.02% | 2920/4394 |
| 近两年 | 36.51% | 2052/2954 |
| 近三年 | 30.11% | 1086/2253 |
| 成立以来 | 29.87% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.69% 678/4961 |
-11.62% 4314/5312 |
- - |
- - |
| 2025 | 15.39% 2549/4813 |
0.62% 1807/3635 |
8.57% 327/4076 |
5.59% 3579/4524 |
0.04% 2266/4813 |
| 2024 | 18.17% 622/3463 |
2.55% 756/2808 |
9.29% 52/3014 |
5.47% 2878/3129 |
-0.03% 1297/3463 |
| 2023 | -2.60% 594/2656 |
3.72% 1140/2280 |
-1.06% 439/2385 |
-2.27% 653/2515 |
-2.89% 551/2655 |
| 2022 | -9.41% 174/2207 |
-2.30% 150/1919 |
-0.67% 1644/2016 |
-12.30% 689/2113 |
6.44% 364/2208 |
| 2021 | 1.70% 657/1822 |
7.20% 80/1255 |
0.86% 1079/1330 |
-1.67% 537/1466 |
-4.34% 1480/1822 |
| 2020 | -2.69% 958/1250 |
-14.53% 965/1028 |
3.88% 924/1067 |
3.86% 966/1164 |
5.53% 781/1184 |
| 2019 | 13.19% 710/1092 |
14.62% 695/754 |
-4.72% 437/804 |
-6.26% 812/850 |
10.58% 119/918 |
| 2018 | - - |
- - |
- - |
- - |
-5.56% 37/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 银河中证沪港深高股息C VS. 长安沪深300非周期A(740101) |